Ok, a tweetorial for the most frequently asked question of this period for all virologists: what will flu do.
I was asked to present how we look at flu in the coming season. First question: what will the COVID 19 pandemic “do” in fall. Restrictions to reduce circulation have really had an impact on flu circulation as well. Look at the global flu surveillance data who.int/tools/flunet
Then question: what happens if there is a two year gap in flu circulation? What does that do to population immunity? This study looked at waning of protective antibodies over time, and estimates 25% reduction over 2 years in unvaccinated individuals.
A specific question is what the role of children will be. There is a large group of young children that has not yet experienced flu. This is measurable, reduced antibodies to some seasonal respiratory viruses in children April 2020 and April 2021 (Sikkema et al)
Next question: what is the infection attack ate in a typical flu season (obviously if there are no measures in place for COVID) . This study estimates 1/5 in children and 1/10 in adults
Uncertain; we have seen substantial excess mortality in the oldest age groups that also are at highest risk for severe flu. Will that result in lower flu impact in the same group?
Then there is the question: which strains will circulate. This is assessed based on surveillance data but there is a gap there too, globally. On the other hand, without much virus circulation, one does not expect a lot of drift, so that works for us I think
So in all, many uncertainties. We do see that flu circulation is starting in Europe, so should be prepared
Note that this data is collected from a network of national influenza centers across the world, that share data on a weekly basis with WHO. In our country, this is a collaboration between @RIVM and @NIVEL and @ErasmusMC. We have a weekly newsletter for wo is interested
@DrJBhattacharya thanks for responding. Few more points. Happy to agree to disagree. You mention topics that I consider to be part of the science advise process, and topics more related to the policy arena and how that works. Sorry, long thread, lost the blue button
I read that your criticism focusses a lot on the second argument and agree evaluation is important. Now there, I think this is very different in different countries, although the same trend (scientists that felt left out) is clear in many places.
I personally believe in the process of evidence synthesis from multiple sources, while maintaining the need for speed. That is how I saw this done in several countries in Europe, with often a key spokesperson conveying the conclusions to policy makers.
@DrJBhattacharya I will give this 1 try. I am looking at your inciting tweets with astonishment. You probably group me in the box of lock down pushers. I wonder if you ever have been in a public health crisis advisory role, hospital outbreak management team, employer health
protection responsibility. Let me explain the way this works: there is an evolving crisis, with lots of uncertainty, but a looming risk of serious impact. That means, there is an immediate and urgent need for detailed data on the evolving situation.
Let's start there: outbreaks typically start messy, particularly when there is a new disease: you have no way of diagnosing yet, you do not know the extend of spread, you do not know who are at risk, who contribute to spread, etc.
Amazing. The scientists ( that challenge my take of things), their institutes, and now also the journals all are corrupt and in the pocket of pharma. Was signed: the head of HHS. This is a direct attack on science, scientists. The sneaky thing is: this narrative builds from
Valid criticism that you will also hear from withon the science community. For instance, if we want to study something, in most organisations this is not like “ yeak great, here you have a pot of money”. No, you write a grant application, that is reviewed ( anonymiusly),
And sometimes selected ( roughly 10% of them). Then you go through all permissions ( medical ethical, animal ethics, biosafety, etc). Then you do the work -usually with a team-, analyse the data, write it up and submit to a journal. There again the work is reviewed , criticised
Shooting the messenger. The person who developed a global network for collaborative surveillance is scapegoated in a political “ trial”. Discussing safety of biosurveillance and details of reporting is one thing. But singling out a single actor and organisation for “ the safety
Of americans” is preposterous. I would suggest that this committee looks at the bovine H5 flu situation in the US, which is teaching material for universities and public health institutes across the globe on how to NOT do outbreak response oversight.house.gov/release/breaki…
I know that this message is going to get response, but would really ask everyone to think this through before shooting the next text: peter Daszak and EHA have been global leaders in our understanding of emerging diseases. Do some reported admin mistakes outweigh that?
1. Een draad nav een belangrijk rapport: Oversterfte obv huisartsen informatie, 1 miljoen personen. Onderzocht in relatie tot vaccinatie (COVID19) , type vaccin, aantallen vaccinaties, en medische voorgeschiedenis.
2. Verschillende leeftijdsgroepen en de griepgroep onder de 60 jaar (de oudere griepgroep zit al in de leeftijdscategorien). Data 2021 in vergelijking met de periode 2015-1018. Oversterfte bekeken binnen drie en twaalf maanden
3. Oversterfte is toegenomen, 913 per 100.000 inwoners in 2019 naar 993, 987 en 961 per 100.000 inwoners in respectievelijk 2020, 2021 en 2022. Onderzoek moeilijk door koppeling gegevens van verschillende bronnen
You only have to read the abstract to see how complex the mpox situation is in DRC. 1) Genetically diverse MPXV lineages co-circulate suggesting multiple zoonotic introductions from one or multiple reservoir species. 2) The Clade Ib expansion in South and North Kivu. 3)
Recent identification of mpox cases in Kinshasa shows multiple virus lineages being present within a large urban center. That shows there is no simple " do this or that" measure to control this. International news has focussed on the increased human - to- medrxiv.org/content/10.110…
human transmission of Clade Ib, which is driving the international outbreaks on Ib, but let us not forget that the picture across DRC is very different with multiple zoonotic spillovers, all leading to smaller outbreaks. That requires different containment measures and an